Short	0	5	B-Gene_or_gene_product
pigment	6	13	I-Gene_or_gene_product
epithelial	14	24	I-Gene_or_gene_product
-	24	25	I-Gene_or_gene_product
derived	25	32	I-Gene_or_gene_product
factor	33	39	I-Gene_or_gene_product
-	39	40	I-Gene_or_gene_product
derived	40	47	I-Gene_or_gene_product
peptide	48	55	I-Gene_or_gene_product
inhibits	56	64	O
angiogenesis	65	77	O
and	78	81	O
tumor	82	87	B-Pathological_formation
growth	88	94	O
.	94	95	O

PURPOSE	97	104	O
:	104	105	O
Pigment	106	113	B-Gene_or_gene_product
epithelial	114	124	I-Gene_or_gene_product
-	124	125	I-Gene_or_gene_product
derived	125	132	I-Gene_or_gene_product
factor	133	139	I-Gene_or_gene_product
(	140	141	O
PEDF	141	145	B-Gene_or_gene_product
)	145	146	O
is	147	149	O
a	150	151	O
potent	152	158	O
angiogenesis	159	171	O
inhibitor	172	181	O
with	182	186	O
multiple	187	195	O
other	196	201	O
functions	202	211	O
,	211	212	O
some	213	217	O
of	218	220	O
which	221	226	O
enhance	227	234	O
tumor	235	240	B-Pathological_formation
growth	241	247	O
.	247	248	O

Our	249	252	O
previous	253	261	O
studies	262	269	O
mapped	270	276	O
PEDF	277	281	B-Gene_or_gene_product
antiangiogenic	282	296	O
and	297	300	O
prosurvival	301	312	O
activities	313	323	O
to	324	326	O
distinct	327	335	O
epitopes	336	344	O
.	344	345	O

This	346	350	O
study	351	356	O
was	357	360	O
aimed	361	366	O
to	367	369	O
determine	370	379	O
the	380	383	O
minimal	384	391	O
fragment	392	400	O
of	401	403	O
PEDF	404	408	B-Gene_or_gene_product
,	408	409	O
which	410	415	O
maintains	416	425	O
antiangiogenic	426	440	O
and	441	444	O
antitumor	445	454	B-Pathological_formation
efficacy	455	463	O
.	463	464	O

EXPERIMENTAL	465	477	O
DESIGN	478	484	O
:	484	485	O
We	486	488	O
analyzed	489	497	O
antigenicity	498	510	O
,	510	511	O
hydrophilicity	512	526	O
,	526	527	O
and	528	531	O
charge	532	538	O
distribution	539	551	O
of	552	554	O
the	555	558	O
angioinhibitory	559	574	O
epitope	575	582	O
(	583	584	O
the	584	587	O
34	588	590	O
-	590	591	O
mer	591	594	O
)	594	595	O
and	596	599	O
designed	600	608	O
three	609	614	O
peptides	615	623	O
covering	624	632	O
its	633	636	O
COOH	637	641	O
terminus	642	650	O
,	650	651	O
P14	652	655	B-Gene_or_gene_product
,	655	656	O
P18	657	660	B-Gene_or_gene_product
,	660	661	O
and	662	665	O
P23	666	669	B-Gene_or_gene_product
.	669	670	O

We	671	673	O
analyzed	674	682	O
their	683	688	O
ability	689	696	O
to	697	699	O
block	700	705	O
endothelial	706	717	B-Cell
cell	718	722	I-Cell
chemotaxis	723	733	O
and	734	737	O
induce	738	744	O
apoptosis	745	754	O
in	755	757	O
vitro	758	763	O
and	764	767	O
their	768	773	O
antiangiogenic	774	788	O
activity	789	797	O
in	798	800	O
vivo	801	805	O
.	805	806	O

The	807	810	O
selected	811	819	O
peptide	820	827	O
was	828	831	O
tested	832	838	O
for	839	842	O
the	843	846	O
antitumor	847	856	B-Pathological_formation
activity	857	865	O
against	866	873	O
mildly	874	880	O
aggressive	881	891	O
xenografted	892	903	O
prostate	904	912	B-Pathological_formation
carcinoma	913	922	I-Pathological_formation
and	923	926	O
highly	927	933	O
aggressive	934	944	O
renal	945	950	B-Pathological_formation
cell	951	955	I-Pathological_formation
carcinoma	956	965	I-Pathological_formation
.	965	966	O

To	967	969	O
verify	970	976	O
that	977	981	O
P18	982	985	B-Gene_or_gene_product
acts	986	990	O
in	991	993	O
the	994	997	O
same	998	1002	O
manner	1003	1009	O
as	1010	1012	O
PEDF	1013	1017	B-Gene_or_gene_product
,	1017	1018	O
we	1019	1021	O
used	1022	1026	O
immunohistochemistry	1027	1047	O
to	1048	1050	O
measure	1051	1058	O
PEDF	1059	1063	B-Gene_or_gene_product
targets	1064	1071	I-Gene_or_gene_product
,	1071	1072	O
vascular	1073	1081	B-Gene_or_gene_product
endothelial	1082	1093	I-Gene_or_gene_product
growth	1094	1100	I-Gene_or_gene_product
factor	1101	1107	I-Gene_or_gene_product
receptor	1108	1116	I-Gene_or_gene_product
2	1117	1118	I-Gene_or_gene_product
,	1118	1119	O
and	1120	1123	O
CD95	1124	1128	B-Gene_or_gene_product
ligand	1129	1135	I-Gene_or_gene_product
expression	1136	1146	O
in	1147	1149	O
P18	1150	1153	B-Gene_or_gene_product
-	1153	1154	O
treated	1154	1161	O
vasculature	1162	1173	B-Multi-tissue_structure
.	1173	1174	O

RESULTS	1175	1182	O
:	1182	1183	O
P14	1184	1187	B-Gene_or_gene_product
and	1188	1191	O
P18	1192	1195	B-Gene_or_gene_product
blocked	1196	1203	O
endothelial	1204	1215	B-Cell
cell	1216	1220	I-Cell
chemotaxis	1221	1231	O
;	1231	1232	O
P18	1233	1236	B-Gene_or_gene_product
and	1237	1240	O
P23	1241	1244	B-Gene_or_gene_product
induced	1245	1252	O
apoptosis	1253	1262	O
.	1262	1263	O

P18	1264	1267	B-Gene_or_gene_product
showed	1268	1274	O
the	1275	1278	O
highest	1279	1286	O
IC50	1287	1291	O
and	1292	1295	O
blocked	1296	1303	O
angiogenesis	1304	1316	O
in	1317	1319	O
vivo	1320	1324	O
:	1324	1325	O
P23	1326	1329	B-Gene_or_gene_product
was	1330	1333	O
inactive	1334	1342	O
and	1343	1346	O
P14	1347	1350	B-Gene_or_gene_product
was	1351	1354	O
proangiogenic	1355	1368	O
.	1368	1369	O

P18	1370	1373	B-Gene_or_gene_product
increased	1374	1383	O
the	1384	1387	O
production	1388	1398	O
of	1399	1401	O
CD95	1402	1406	B-Gene_or_gene_product
ligand	1407	1413	I-Gene_or_gene_product
and	1414	1417	O
reduced	1418	1425	O
the	1426	1429	O
expression	1430	1440	O
of	1441	1443	O
vascular	1444	1452	B-Gene_or_gene_product
endothelial	1453	1464	I-Gene_or_gene_product
growth	1465	1471	I-Gene_or_gene_product
factor	1472	1478	I-Gene_or_gene_product
receptor	1479	1487	I-Gene_or_gene_product
2	1488	1489	I-Gene_or_gene_product
by	1490	1492	O
the	1493	1496	O
endothelial	1497	1508	B-Cell
cells	1509	1514	I-Cell
in	1515	1517	O
vivo	1518	1522	O
.	1522	1523	O

In	1524	1526	O
tumor	1527	1532	B-Pathological_formation
studies	1533	1540	O
,	1540	1541	O
P18	1542	1545	B-Gene_or_gene_product
was	1546	1549	O
more	1550	1554	O
effective	1555	1564	O
in	1565	1567	O
blocking	1568	1576	O
the	1577	1580	O
angiogenesis	1581	1593	O
and	1594	1597	O
growth	1598	1604	O
of	1605	1607	O
the	1608	1611	O
prostate	1612	1620	B-Pathological_formation
cancer	1621	1627	I-Pathological_formation
than	1628	1632	O
parental	1633	1641	B-Gene_or_gene_product
34	1642	1644	I-Gene_or_gene_product
-	1644	1645	I-Gene_or_gene_product
mer	1645	1648	I-Gene_or_gene_product
;	1648	1649	O
in	1650	1652	O
the	1653	1656	O
renal	1657	1662	B-Pathological_formation
cell	1663	1667	I-Pathological_formation
carcinoma	1668	1677	I-Pathological_formation
,	1677	1678	O
P18	1679	1682	B-Gene_or_gene_product
strongly	1683	1691	O
decreased	1692	1701	O
angiogenesis	1702	1714	O
and	1715	1718	O
halted	1719	1725	O
the	1726	1729	O
progression	1730	1741	O
of	1742	1744	O
established	1745	1756	O
tumors	1757	1763	B-Pathological_formation
.	1763	1764	O

CONCLUSIONS	1765	1776	O
:	1776	1777	O
P18	1778	1781	B-Gene_or_gene_product
is	1782	1784	O
a	1785	1786	O
novel	1787	1792	O
and	1793	1796	O
potent	1797	1803	O
antiangiogenic	1804	1818	O
biotherapeutic	1819	1833	O
agent	1834	1839	O
that	1840	1844	O
has	1845	1848	O
potential	1849	1858	O
to	1859	1861	O
be	1862	1864	O
developed	1865	1874	O
for	1875	1878	O
the	1879	1882	O
treatment	1883	1892	O
of	1893	1895	O
prostate	1896	1904	B-Pathological_formation
and	1905	1908	O
renal	1909	1914	B-Pathological_formation
cancer	1915	1921	I-Pathological_formation
.	1921	1922	O

